Clinical trial
Multi-center, Randomized, Placebo-controlled, Double-blind Phase 1b/2a Trial to Investigate Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Invobenitug Also Known as Procizumab (PCZ; AK1967) in Patients With Cardiogenic Shock and Elevated Circulating Dipeptidyl Peptidase 3 (cDPP3) Concentrations.
NCT06832722 is registered in ClinicalTrials.gov with 4TEEN4 Pharmaceuticals GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multi-center, Randomized, Placebo-controlled, Double-blind Phase 1b/2a Trial to Investigate Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Invobenitug Also Known as Procizumab (PCZ; AK1967) in Patients With Cardiogenic Shock and Elevated Circulating Dipeptidyl Peptidase 3 (cDPP3) Concentrations.
- Lead sponsor
- 4TEEN4 Pharmaceuticals GmbH
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- July 13, 2025
- Completion date
- December 31, 2026
- Enrollment
- 90 (estimated)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.